Compounded Tirzepatide in 2026: What Prescribers and Pharmacists Need to Know

Is compounded tirzepatide still legal in 2026?

For the vast majority of prescriptions, no. Tirzepatide — the active ingredient in Eli Lilly's Mounjaro and Zepbound — came off FDA's drug shortage list on October 2, 2024, and FDA reaffirmed that resolution in a December 19, 2024 declaratory order [1]. Once the shortage ended, the shortage-based compounding pathway under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act closed.

A 503A state-licensed pharmacy may still compound tirzepatide for an individual, identified patient when the prescriber documents a clinical difference the FDA-approved product cannot meet — for example, a verified allergy to an inactive ingredient in Zepbound or Mounjaro. Compounding for price, convenience, or general weight loss does not qualify and is treated as producing a copy of a commercially available drug.

Compounded tirzepatide is not a category of its own. It is either a patient-specific 503A preparation backed by a documented clinical need, or it is an unlawful copy.

---

How we got here: the FDA and court timeline

The regulatory posture changed quickly over 2024–2025. The table below captures the milestones that matter for any pharmacist or prescriber reviewing a current prescription.

The Northern District of Texas ruling is the linchpin. Once the court declined to enjoin FDA, the agency's shortage resolution and its enforcement timeline became operative — and 503A compounders lost the legal ground they had been standing on during the shortage.

---

What 503A pharmacies can and cannot do now

Section 503A permits a state-licensed pharmacist or physician to compound a drug product for an identified individual patient based on a valid prescription, subject to several conditions — including that the compound is not "essentially a copy" of a commercially available drug unless there is a documented clinical difference for that patient.

With tirzepatide now commercially available, the "essentially a copy" prohibition controls. A 503A pharmacy may fill a tirzepatide prescription only if all of the following are true:

1. The prescription is for a specific, identified patient — not a batch or a telehealth intake form routed to a generic protocol.
2. The prescribing clinician has documented, in writing, a clinical change from the FDA-approved product that produces a significant difference for that patient (a verified excipient allergy is the clearest example).
3. The pharmacy retains the prescription-specific documentation and does not compound "regularly or in inordinate amounts" as defined under 503A(b)(1)(D).
4. The compound is not produced in a commercial dose-and-route combination that mirrors Zepbound or Mounjaro (multi-dose vials marketed as lower-cost alternatives are the clearest violation).

Operationally, a pharmacy that fills dozens of identical tirzepatide prescriptions per week for telehealth weight-loss patients is not practicing patient-specific compounding — it is producing copies, and that is the conduct FDA and the courts have now flagged as outside the statute.

---

503B outsourcing facilities: tirzepatide is off the list

503B outsourcing facilities operate under a different framework. They can produce drugs in bulk without patient-specific prescriptions, but only from substances on FDA's 503B bulks list — or, during a shortage, from a drug appearing on the shortage list.

Tirzepatide has never been added to FDA's 503B bulks list. Once it came off the shortage list, the only legal pathway for 503B compounding of tirzepatide closed. FDA's enforcement discretion for 503Bs expired March 19, 2025, and the agency has since signaled it intends to act against outsourcing facilities continuing to produce tirzepatide copies [4].

The practical takeaway for pharmacists: if a 503B vendor is still offering tirzepatide in multi-dose vials in 2026, that vendor is operating outside the FD&C Act. Accepting product from them exposes the dispensing pharmacy to board action and product-liability risk.

---

How TrumpRx changes the compounding calculus

The economic driver for compounded tirzepatide was always price. Brand Zepbound was listed above $1,000 per month, pushing cash-pay patients toward compounded alternatives at a fraction of the cost. The November 2025 Most-Favored-Nation agreement between the Trump administration and Eli Lilly changes that equation.

Under the deal, Zepbound vials are sold through LillyDirect via the TrumpRx platform at pricing that starts around $299 per month, with an average around $346 [5],[6]. Medicare and state Medicaid programs pay $245 per month, and Medicare beneficiaries have a $50 copay for the first time for an obesity indication [5]. The platform launched in January 2026 and routes tirzepatide orders directly to Lilly's fulfillment system [6].

For regulators, this matters on two fronts:

• Access. FDA's "commercially available" determination is strengthened when the brand is reachable at cash prices in the low-$300s. An argument that compounding is necessary because patients cannot access the drug is much harder to sustain.
• Enforcement posture. When a lower-priced manufacturer channel exists, a compounding pharmacy's defense that it is filling a genuine access gap collapses. Expect FDA and state boards to cite TrumpRx availability when evaluating whether continued compounding meets the 503A patient-specific standard.

For prescribers, TrumpRx is now the default affordability conversation for a cash-pay patient. A compounded tirzepatide prescription written "because the brand is too expensive" is no longer defensible on the record.

---

State board considerations

Federal enforcement is only half the picture. State boards of pharmacy have their own authority over compounding practice, and several have issued guidance or disciplinary actions tied to GLP-1 compounding. A few patterns worth tracking:

• Alignment with FDA. Most state boards treat FDA's enforcement discretion deadlines as binding on state licensees. A 503A pharmacy compounding tirzepatide after February 18, 2025 is presumptively out of compliance absent documented patient-specific justification.
• Telehealth scrutiny. Boards in Florida, Texas, and California have increased inspection of pharmacies tied to high-volume telehealth platforms, where the "individual prescription" framing frequently breaks down under audit.
• Salt-form warnings. FDA has been explicit that tirzepatide sodium and similar salt forms are not the same active ingredient as the approved drug and are not eligible for compounding under 503A. State boards are citing this when pharmacies attempt to reframe their product as a distinct substance.

See also our 50-state telehealth prescribing guide for how remote GLP-1 prescribing intersects with state practice acts.

---

Compliance checklist for prescribers and pharmacists

Before writing or filling a compounded tirzepatide prescription in 2026, confirm:

1. Clinical difference documented. The patient chart identifies a specific reason the FDA-approved product cannot be used — typically a verified allergy to an inactive ingredient. "Cost" is not a clinical difference.
2. Individual patient prescription. The prescription is for a named patient, not a protocol applied across a panel.
3. 503A pharmacy, not 503B. 503B outsourcing facilities have no lawful pathway to tirzepatide in 2026.
4. Source and form verified. The compound uses tirzepatide base from a legitimate API source — not a salt form, not an oral formulation (no oral tirzepatide is FDA-approved in any form).
5. TrumpRx alternative considered. The record reflects that the prescriber evaluated commercially available Zepbound or Mounjaro, including TrumpRx-priced options, before ordering a compound.
6. State board rules checked. Your state's pharmacy practice act may impose additional documentation or reporting above the federal floor.

If any of these steps cannot be satisfied on the record, the safer path is to direct the patient to FDA-approved tirzepatide through a standard commercial, Medicare, Medicaid, or TrumpRx channel.

---

References

1. https://www.fda.gov/media/184606/download

2. https://www.fda.gov/drugs/drug-shortages

3. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

4. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-drug-shortages

5. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/

6. https://trumprx.gov/p/zepbound